APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma
CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...
103 Views
Takeda Pharmaceutical (4502 JP): Decent 9MFY26 Show; Guidance Revision Amid New Leg of Growth
​Takeda Pharmaceutical reports 9MFY26 result with revenue declining 3%. The company raised FY26 forecasts on cost discipline and FX tailwind....
382 Views
Takeda (4502 JP) 2026 Update – We Maintain Our Bearish View!
​Takeda's recent outperformance is overshadowed by concerns about its portfolio and valuation, leading to skepticism about its premium.
301 Views
CHINA/HK: AI & RX - Together At Last !!
China's AI-driven drug discovery (AIDD) sector is growing rapidly, with leading drug and biotech companies entering R&D and drug-development...
112 Views
APAC Healthcare Weekly (August 9) – Hengrui, CSPC Pharma, Takeda Pharma, Otsuka, Alteogen
Hengrui’s trastuzumab rezetecan got 3rd indication approval in China. CSPC and AstraZeneca form JV for biologics manufacturing facility in China....
122 Views